脂质障碍治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

血脂障碍治疗市场按适应症(高胆固醇血症、异常β脂蛋白血症、家族性合并高脂血症等)、分销渠道和地理位置进行细分

市场快照

CAGR
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

导致脂质紊乱治疗市场增长的主要因素是肥胖等生活方式疾病的日益流行以及吸烟和饮酒的增加。生活方式疾病是与人们生活方式有关的疾病。它们包括动脉粥样硬化、心脏病、中风、肥胖和 2 型糖尿病。根据世界卫生组织 (WHO) 的数据,2016 年,超过 19 亿 18 岁及以上的成年人超重。其中超过 6.5 亿人肥胖,但在 2018 年,有 4000 万 5 岁以下儿童超重或肥胖。 

此外,家族性合并高脂血症发病率的不断增长也对市场的增长起到了重要作用。然而,治疗中涉及的药物的副作用是对市场增长的制约。

报告范围

根据报告的范围,血脂紊乱包括影响血脂水平的广泛疾病。通常,它与血脂水平升高有关。 

By Indication
Hypercholesterolemia
Dysbetalipoproteinemia
Familial Combined Hyperlipidemia
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

家族性合并高脂血症发病率有望呈现高增长

家族性合并高脂血症是最常见的先天性血脂升高疾病。它会导致高胆固醇和高甘油三酯,从而导致早期心脏病发作。这种疾病在成人中的发病率很高,该疾病的治疗市场对于参与药物制造的关键参与者来说是有利可图的。由于这种情况很常见,因此治疗这种疾病的药物具有最大的销售额并产生最大的收入。 

他汀类药物是用于治疗家族性合并高脂血症的一类药物,同样用于治疗肥胖等相关疾病。因此,随着肥胖症发病率的增加,该细分市场的市场增长率也随之增加。 

根据国家罕见疾病组织 (NORD) 的数据,每 220 人中就有 1 人患有家族性合并高脂血症,这些统计数据证明,患者数量的增加与市场增长成正比。

Obesity.png

北美在市场上占主导地位,预计在预测期内也会如此

在整个预测期内,预计北美将主导整个脂质疾病治疗市场。市场增长是由于关键参与者的存在、该地区肥胖和其他生活方式障碍的高发病率、已建立的医疗保健基础设施等因素,这些是其在市场中占有很大份额的一些关键因素。 

此外,更高的家族性合并高脂血症发病率、有益的政府举措和提高对治疗的认识是预计会增加市场增长的一些驱动因素。在北美地区,美国占有最大的市场份额。根据慢性病预防中心 (CDC) 的数据,美国 7% 的 6 至 19 岁儿童和青少年总胆固醇偏高,因此预计该国越来越多的此类疾病将刺激该地区的需求。

Dilated Cardiomyopathy Therapeutic Market

竞争格局

脂质疾病治疗市场竞争适度,由主要参与者组成。目前主导市场的一些公司辉瑞公司、诺华公司、阿斯利康公司、默克公司、Sun Pharma、Emcure Pharmaceuticals、Teva Pharmaceuticals、Mylan Pharmaceuticals, Inc.、Kowa Pharmaceuticals America, Inc.、 Glenmark Pharmaceuticals Ltd.、Wockhardt Limited。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Prevalence of Several Lifestyle Diseases

      2. 4.2.2 Rise in the Smoking and Alcohol Consumption

    3. 4.3 Market Restraints

      1. 4.3.1 Side effects of the treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Indication

      1. 5.1.1 Hypercholesterolemia

      2. 5.1.2 Dysbetalipoproteinemia

      3. 5.1.3 Familial Combined Hyperlipidemia

      4. 5.1.4 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Online Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer, Inc

      2. 6.1.2 Novartis AG

      3. 6.1.3 Astrazeneca Plc

      4. 6.1.4 Merck & Co. Inc.

      5. 6.1.5 Emcure Pharmaceuticals Ltd.

      6. 6.1.6 Ranbaxy Laboratories Ltd.

      7. 6.1.7 Teva Pharmaceuticals

      8. 6.1.8 Mylan Pharmaceuticals, Inc.

      9. 6.1.9 Kowa Pharmaceuticals America, Inc.

      10. 6.1.10 Glenmark Pharmaceuticals Ltd.

      11. 6.1.11 Sun Pharmaceuticals Industries Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Lipid Disorder Treatment Market market is studied from 2018 - 2026.

The Lipid Disorder Treatment Market is growing at a CAGR of 7.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Pfizer, Inc, Novartis AG, Astrazeneca Plc, Merck & Co., Inc, Sun Pharma are the major companies operating in Lipid Disorder Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!